Welcome to our dedicated page for First Wave BioPharma SEC filings (Ticker: FWBI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech 10-K packed with clinical jargon, dilution tables, and FDA milestones can be overwhelming. First Wave BioPharma’s disclosures are no exception—each filing hides details on MS1819 trial data, cash runway, and partnership revenue that drive valuation, yet those points are scattered across hundreds of pages.
Stock Titan solves that problem. Our AI distills every First Wave BioPharma SEC filing—whether a quarterly earnings report 10-Q filing or an 8-K material event—into clear language and pinpointed data. Need to track First Wave BioPharma insider trading Form 4 transactions? You’ll receive real-time alerts the moment executives file. Trying to compare R&D spend quarter over quarter? The platform highlights changes automatically, making understanding First Wave BioPharma SEC documents with AI effortless.
Here’s what you can explore today:
- Annual report 10-K simplified for pipeline timelines, going-concern notes, and risk factors
- First Wave BioPharma proxy statement executive compensation that details incentive alignment
- First Wave BioPharma Form 4 insider transactions real-time to gauge management confidence
- First Wave BioPharma earnings report filing analysis that explains trial spend versus cash reserves
- First Wave BioPharma 8-K material events explained so surprises never slip past you
Every document is indexed, searchable, and annotated. Investors use these insights to monitor cash-burn, validate dilution risk, and understand when clinical results might shift the outlook. Stop scrolling through dense PDFs—get the biotech specifics you need from First Wave BioPharma SEC filings explained simply, powered by Stock Titan’s AI.
Campbell Soup Company (CPB) Form 4 filing – insider activity. On 26 June 2025, Director Sarah Hofstetter acquired 1,348.51 units of phantom stock, an award whose value mirrors one share of common stock. The units were granted at a stated price of $0 under the company’s Supplemental Retirement Plan and are fully vested. After the transaction, Hofstetter’s total phantom-stock holdings rose to 25,710.86 units, which now include 262.25 units accumulated through dividend reinvestment since her last report. Phantom stock will be settled in cash upon the director’s retirement, resignation, or termination. No sales or disposals were reported, and there were no changes in non-derivative common-stock ownership.
Because the award represents routine director compensation and has an estimated market value far below materiality thresholds relative to Campbell’s market capitalisation, the filing is considered informational rather than market-moving. Nevertheless, the absence of sales and the continuing accumulation of stock-equivalent units signal ongoing alignment of director interests with shareholder value.
Entero Therapeutics, Inc. has filed Amendment No. 2 to its Form S-1 registration statement, signalling its intent to raise new equity capital through a public offering.
The company plans to offer 12,000,000 shares of common stock, with an estimated public offering price of $0.50 per share, based on the June 16, 2025 Nasdaq closing price. In parallel, Entero is registering 12,000,000 pre-funded warrants, each exercisable for one common share at an exercise price of $0.0001. The warrants are designed for investors who would otherwise exceed 4.99% (optionally 9.99%) ownership immediately after the offering. The common shares trade on Nasdaq under the ticker “ENTO.” The pre-funded warrants will not be listed.
The sole book-runner is WestPark Capital, Inc. Underwriting terms include customary discounts, commissions and a non-accountable expense allowance up to $45,000. Proceeds to the company, net of underwriting discounts but before expenses and any warrant exercise, will depend on the final negotiated price. Entero is classified as both a non-accelerated filer and a smaller reporting company, allowing reduced disclosure requirements.
The filing reiterates that investing in the company’s securities involves a high degree of risk, with detailed risks beginning on page 18 of the prospectus. The company has not yet disclosed the expected closing date for delivery of securities, indicating that details may change prior to effectiveness.